Table 1.
Demographics and Clinical Characteristics of the patients in the development and validation cohorts
| development cohort (n = 392) | validation cohort (n = 178) | |
|---|---|---|
| Demographics | ||
| Age, y, median (IQR) | 70(60–79) | 72(61–81) |
| Age > 60 y, n (%) | 287(73.2) | 136(76.4) |
| Male sex, n (%) | 236(60.2) | 102(57.3) |
| Medical history, n (%) | ||
| Hypertension | 288(73.5) | 131(73.6) |
| Diabetes mellitus | 125(31.9) | 62(34.8) |
| Previous stroke | 53(13.5) | 50(28.1) |
| Atrial fibrillation | 80(20.9) | 36(20.2) |
| Antiplatelet | 53(13.5) | 48(27.0) |
| Oral anticoagulant | 13(3.3) | 21(11.8) |
| Smoking current | 147(37.5) | 62(34.8) |
| Baseline data, median (IQR) | ||
| Systolic BP, mm Hg, | 153(137–171) | 157(138–175) |
| Diastolic BP, mm Hg, | 88(80–99) | 88(77–99) |
| Temperature,°C | 36.5(36.4–36.7) | 36.5(36.2–36.7) |
| Glucose, mmol/L | 6.32(5.15–8.31) | 7.47(6.15–9.59) |
| Total cholesterol (TC), mmol/L | 4.78(4.06–5.45) | 4.81(4.08–5.58) |
| Triglyceride (TG), mmol/L | 1.33(1.01–1.88) | 1.51(1.06–2.33) |
| High-density lipoprotein (HDL), mmol/L | 1.06(0.91–1.25) | 1.39(1.14–1.65) |
| Low-density lipoprotein (LDL), mmol/L | 2.90(2.20–3.51) | 2.76(2.17–3.31) |
| Blood platelet (PLT), × 109/L | 179.00(135.25–215.75) | 194.00(154.75–226.50) |
| Prothrombin time (PT)% | 99.00(90.00–109.00) | 91.64(81.34–101.97) |
| APTT, s | 35.20(32.40–37.88) | 28.40(26.00–30.53) |
| INR | 1.00(0.95–1.07) | 1.04(0.99–1.10) |
| Fibrous Protein (Fib), g/L | 3.29(2.84–3.94) | 3.04(2.57–3.52) |
| Imaging data, median (IQR) | ||
| Cerebral Infarction Area (CIA), cm2 | 3.00(1.00–9.69) | 3.16(0.99–19.09) |
| Cerebral Infarction Volume (CIV), cm3 | 3.87(0.78–19.31) | 3.78(0.72–43.28) |
| Scores | ||
| THRIVE score, median (IQR) | 2.00(2.00–3.75) | 3.00(2.00–4.00) |
| NIHSS score, median (IQR) | 5(3–9) | 6 (4–16) |
| NIHSS score > 20, n (%) | 11(2.8) | 22(12.7) |
| Treament | ||
| onset-to-treatment (OTT), h, median (IQR) | 13.50(5.00–48.00) | 7.00(2.00–24.00) |
| Thrombolysis or ET, n (%) | 21(5.4) | 32(18.5) |
APTT activated partial thromboplastin time, INR international normalized ratio, NIHSS National Institutes for Health Stroke Scale